Aurobindo’s Eugia Prepares For ‘Muted’ Growth In FY2025
Ongoing Issues With Eugia Plant Made A Dent In Business
While Eugia continues to look for ways to solve the future challenges amidst temporary plant closure, parent Aurobindo reported a “good” performance in FY2024, with expected continued growth, and gave an update on its Auro Peptides business and GLP-1s.
